Gilead Sciences, Inc. is rated a Buy with robust profitability, solid dividend, prudent M&A and 15-20% upside potential. Read ...
6h
NanoViricides, Inc. Has Filed its Quarterly Report – Subsequent Raise Has Fortified Fiscal Position
SHELTON, CONNECTICUT / ACCESS Newswire / November 17, 2025 / NanoViricides, Inc. (NYSE Amer.:NNVC) (the “Company”), reports that it has filed its Quarterly Report on Form 10-Q for the fiscal quarter ...
SAS Viya Essentials rapidly deploys select SAS Viya products using SAS Managed Cloud Services Thursday, 20 November 2025 - SAS, a global ...
Patient advocacy groups urged the South African government to issue a compulsory license for a groundbreaking HIV prevention ...
LGBTQ Nation on MSN
U.S. ships groundbreaking HIV drug to Africa, but slashed funding threatens progress
The U.S. just shipped two million doses of lenacapavir, a groundbreaking twice-a-year HIV-prevention injectable medication, ...
Clinical Trials Arena on MSN
MSD’s once-daily HIV pill non-inferior to Biktarvy in Phase III trial
MSD announced the data just days after Gilead also touted success with a once-daily antiretroviral therapy (ART).
Initial results of ongoing investigator-initiated proof-of-concept trial demonstrate crofelemer can potentially extend the lives of infants born with intestinal failure due to microvillus inclusion ...
The Biotech Growth Trust PLC - Half-year Financial Report ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback